Recursion completed the acquisition of Vium.

Recursion, a digital biology company industrializing drug discovery, completed the acquisition of Vium, a creator of a fully digital end to end Digital Vivarium platform which is transforming in vivo research. Financial terms were not disclosed. “Bringing the fantastic team at Vium in-house will enable us to build on our core technology and vision, augmenting our huge in vitro datasets with large, complementary in vivo datasets, and advancing our mission to decode biology to radically improve patient lives,” Chris Gibson, Recursion Co-Founder and CEO.